Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Tuesday

Aquestive Therapeutics (NASDAQ:AQST) will be announcing its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.08). The company had revenue of $12.05 million during the quarter, compared to the consensus estimate of $12.22 million. During the same period last year, the firm earned $0.11 earnings per share. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aquestive Therapeutics Stock Performance

AQST stock traded down $0.09 on Tuesday, reaching $3.73. The company’s stock had a trading volume of 347,983 shares, compared to its average volume of 1,961,240. The business has a fifty day simple moving average of $2.84 and a two-hundred day simple moving average of $3.31. Aquestive Therapeutics has a 12-month low of $1.25 and a 12-month high of $6.23.

Wall Street Analyst Weigh In

A number of analysts recently commented on AQST shares. Piper Sandler began coverage on Aquestive Therapeutics in a research note on Thursday, April 11th. They issued an “overweight” rating and a $10.00 price target for the company. SVB Leerink began coverage on Aquestive Therapeutics in a report on Friday, May 10th. They issued an “outperform” rating and a $8.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a report on Friday. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a report on Wednesday, June 26th. Finally, Leerink Partnrs upgraded Aquestive Therapeutics to a “strong-buy” rating in a report on Friday, May 10th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $7.83.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.